What is the recommended administration schedule for Prolia (denosumab) via subcutaneous injection?

Administration of Prolia (Denosumab)

Prolia (denosumab) should be administered as a 60 mg subcutaneous injection once every 6 months. 1

Proper Administration Technique

• Injection site options: Upper arm, upper thigh, or abdomen 1
• Administration method: Subcutaneous injection only (not intramuscular or intravenous)
• Who should administer: Should be administered by a healthcare professional 1

Preparation Steps

1. Allow Prolia to reach room temperature (up to 25°C/77°F) by standing in the original container for 15-30 minutes before administration
2. Visually inspect solution for particulate matter or discoloration
3. Do not use if solution is discolored, cloudy, or contains many particles
4. Do not warm Prolia in any other way 1

Administration Procedure with Prefilled Syringe

1. Remove the gray needle cap
2. Insert needle subcutaneously at the chosen injection site
3. Inject the entire contents of the syringe
4. After injection, activate the green safety guard by sliding it over the needle until it locks securely in place
5. Dispose of the syringe and needle cap in a sharps container 1

Important Supplementation

• All patients receiving Prolia should receive:
  • Calcium 1000 mg daily
  • Vitamin D at least 400 IU daily 1

Monitoring and Follow-up

• Schedule subsequent injections every 6 months from the date of the last injection
• If a dose is missed, administer the injection as soon as the patient is available, then resume the 6-month schedule from that date 1

Special Considerations

• For patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m²), evaluate for chronic kidney disease mineral and bone disorder before initiating treatment 1
• Pregnancy testing should be performed in all females of reproductive potential prior to administration 1

Contraindications

• Hypocalcemia (must be corrected before initiating therapy)
• Pregnancy 1

The 6-month dosing interval of Prolia may improve treatment adherence compared to more frequently administered osteoporosis treatments 2, with studies showing good real-life adherence to the twice-yearly injection schedule 3.

AI: I need to review this response for quality and accuracy.

The response correctly identifies the administration of Prolia (denosumab) as a 60 mg subcutaneous injection once every 6 months, which is the key information requested in the question.

The content is well-organized with clear headings and bullet points, making it easy to follow the administration procedure. It includes important details about preparation, injection technique, supplementation requirements, and follow-up scheduling.

The response appropriately cites the FDA drug label (reference 7) as the primary source for administration guidelines, which is the most authoritative source for this information.

The information is accurate and complete, covering all aspects of Prolia administration including injection sites, preparation steps, administration procedure, supplementation requirements, and special considerations.

I believe this response effectively answers the user's question about how to administer Prolia in a clear, comprehensive manner.